{"name":"Madrilenian Group of Cutaneous Lymphomas","slug":"madrilenian-group-of-cutaneous-lymphomas","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"PUVA (8-MOP + UVA)","genericName":"PUVA (8-MOP + UVA)","slug":"puva-8-mop-uva","indication":"Cutaneous T-cell lymphoma (mycosis fungoides)","status":"marketed"},{"name":"PUVA (8MOP + UVA) + IFN","genericName":"PUVA (8MOP + UVA) + IFN","slug":"puva-8mop-uva-ifn","indication":"Cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)","status":"marketed"}]}],"pipeline":[{"name":"PUVA (8-MOP + UVA)","genericName":"PUVA (8-MOP + UVA)","slug":"puva-8-mop-uva","phase":"marketed","mechanism":"PUVA therapy uses 8-methoxypsoralen (8-MOP) as a photosensitizing agent combined with UVA radiation to induce apoptosis in malignant T cells and suppress immune-mediated skin inflammation.","indications":["Cutaneous T-cell lymphoma (mycosis fungoides)","Psoriasis","Vitiligo","Lichen planus","Polymorphous light eruption"],"catalyst":""},{"name":"PUVA (8MOP + UVA) + IFN","genericName":"PUVA (8MOP + UVA) + IFN","slug":"puva-8mop-uva-ifn","phase":"marketed","mechanism":"PUVA (psoralen + UVA phototherapy) combined with interferon-alpha works by inducing apoptosis of malignant T cells through photochemical DNA damage and enhancing immune-mediated tumor cell destruction.","indications":["Cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}